
Full text loading...
Category: Bacterial Pathogenesis
Development of a Human Vaccine, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555815554/9781555814373_Chap24-1.gif /docserver/preview/fulltext/10.1128/9781555815554/9781555814373_Chap24-2.gifAbstract:
Observational and experimental studies provide evidence of acquired immunity developing in humans exposed to Campylobacter jejuni, lending support for vaccine development. Campylobacter vaccine development strategy must integrate basic science knowledge of pathogenesis and immunity, as well as an appreciation of the antigens and host responses associated with the development of protective immunity. More practical concerns include the need to optimize vaccine production methodology, delivery methods, and regimen selection followed by an assessment of vaccine safety, immunogenicity, and efficacy in target populations. The major impact of diarrheal disease in industrialized countries such as the United States relates to short-term morbidity and economic burden. Surveys among travel medicine practitioners in the United States and the United Kingdom have provided estimates on the level of support and potential application for vaccines to prevent traveler’s diarrhea (TD), and specifically, Campylobacter-only vaccines. The survey was limited by low response rate but was able to assess providers providing care in high-volume practices. A major consideration in the development of any vaccine is safety. For Campylobacter, this includes symptoms that may be caused by a vaccine in the first 24 to 72 h, as well as the potential for postvaccination sequelae a few weeks after immunization. Campylobacter vaccine development at the U.S. Naval Medical Research Center recently completed clinical studies of subunit Campylobacter vaccine based on the flagellin protein. Increased understanding of the burden of campylobacteriosis combined with evidence of acquired immunity provides the need and rationale for disease prevention strategies that include vaccine approaches.
Full text loading...